A satirical X post saying the three major insulin manufacturers in the United States had announced 2,000%-3,000% price ...

Eli Lilly And Co (LLY) stock saw a modest uptick, ending the day at $808.17 which represents a slight increase of $22.76 or 2.90% from the prior close of $785.41. The stock opened at $780.91 and ...

MSNBC anchor Alex Witt corrected correspondent Priya Sridhar during her on-air report on the DEA arresting members of illegal ...

The Thurgood Marshall College Fund has received a $25 million grant by the Lilly Endowment to help fund its HBCU-focused ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as particularly promising.

Novo Nordisk, the largest European company by market capitalization, has achieved worse than expected results for its new ...

Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...

Pharmaceutical giants Eli Lilly and Novo Nordisk, makers of Zepbound and Wegovy, respectively, have filed lawsuits against medical spas, weight-loss clinics, and compounding pharmacies they accuse of ...

Eli Lilly (NYSE: LLY) is the maker of one of today's most in-demand ... Meta Platforms (NASDAQ: META) is a leader in the ...

Got $5,000? 2 Top Healthcare Stocks to Buy in 2025 and Hold Forever. Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.

Morningstar Research Services’ chief market strategist Dave Sekera discusses where stocks look especially expensive in the US today, as well as pockets of value.